

SUB
D1
CONT.

50. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated mammalian Bcl-xL binding protein, wherein said nucleotide sequence hybridizes to the complement of a nucleotide sequence set forth in SEQ ID NO:1 which encodes a Bcl-xL binding protein in 6X SSC at 45°C, followed by one or more washes in 0.2X SSC, 0.1% SDS at 50-65°C.

C1
CONT.

51. An isolated nucleic acid molecule comprising a nucleotide sequence encoding an isolated mammalian Bcl-xL binding protein as shown in SEQ ID NO:1.

52. A nucleic acid molecule comprising a nucleotide sequence encoding an isolated mammalian Bcl-xL binding domain, wherein said domain is a fragment of the nucleic acid molecule of claim 51.

53. The isolated nucleic acid molecule of claim 52 wherein the isolated Bcl-xL binding domain consists of amino acids 419-559 or amino acids 429-559 of SEQ ID NO:2.

54. The isolated nucleic acid molecule of claim 49, wherein said isolated mammalian Bcl-xL binding protein modulates apoptosis.

SUB
D2

55. The isolated nucleic acid molecule of claim 50, wherein said isolated mammalian Bcl-xL binding protein modulates apoptosis.

56. The isolated nucleic acid molecule of claim 51, wherein said isolated mammalian Bcl-xL binding protein modulates apoptosis.

57. The isolated nucleic acid molecule of claim 49, wherein said nucleic acid molecule encodes a fusion protein.

58. The isolated nucleic acid molecule of claim 50, wherein said nucleic acid molecule encodes a fusion protein.

C1
const.
59. The isolated nucleic acid molecule of claim 51, wherein said nucleic acid molecule encodes a fusion protein.

60. A neural cell line stably expressing a heterologous Pablo polypeptide or an isolated Bcl-xL binding protein set forth in SEQ ID NO:2.

61. An isolated nucleic acid molecule comprising a heterologous nucleotide sequence encoding an isolated mammalian fusion protein having an amino acid sequence of SEQ ID NO:2, wherein the protein modulates apoptosis.

IN THE SPECIFICATION

On page 93, at line 23, replace "reported" with - -predicted- -.

On page 93, at line 24, delete "and to methods of its use".

On page 93, at line 26, delete "from the brain".

REMARKS

The claims are 43-44 and 49-61. Claims 22-42 and 45-48 were withdrawn from consideration by the Examiner in Paper No. 19 as drawn to an unelected Group. New claims